Pictilisib (GDC-0941)

Catalog No.S1065

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.

Price Stock Quantity  
USD 240 In stock
USD 120 In stock
USD 170 In stock
USD 370 In stock
USD 970 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Pictilisib (GDC-0941) Chemical Structure

Pictilisib (GDC-0941) Chemical Structure
Molecular Weight: 513.64

Validation & Quality Control

Product Use Citation(56)

Customer Product Validation(7)

Quality Control & MSDS

Related Compound Libraries

Pictilisib (GDC-0941) is available in the following compound libraries:

PI3K Inhibitors with Unique Features

  • Pan PI3K Inhibitor

    LY294002 Pan-PI3Kα/δ/β inhibitor, IC50=0.5 μM/0.57 μM/0.97 μM.

  • Most Potent PI3K Inhibitor

    Duvelisib (IPI-145, INK1197) PI3K δ, IC50=1 nM.

  • FDA-approved PI3K Inhibitor

    CAL-101 (Idelalisib, GS-1101) Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.

  • Newest PI3K Inhibitor

    GSK2636771 Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Product Information

  • Compare PI3K
    Compare PI3K Products
  • Research Area
  • Inhibition Profile
  • Pictilisib (GDC-0941) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.
Targets p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)

 View  More

IC50 3 nM 3 nM 33 nM 75 nM
In vitro GDC-0941 is equipotent against PI3Kα and PI3Kδ as well as PI3Kα mutants E545-K and H1047-R, displaying modest levels of selectivity against PI3Kβ (10-fold) and PI3Kγ (25-fold), and greater levels of selectivity against members of PI3K class II, III, and IV, including C2β, Vps34, DNA-PK, and mTOR. GDC-0941 potently inhibits the phosphorylation of Akt in U87MG, PC3, and MDA-MB-361 cells with IC50 of 46 nM, 37 nM, and 28 nM, respectively. GDC-0941 inhibits the proliferation of U87MG, A2780, PC3, and MDA-MB-361 cells with IC50 of 0.95 μM, 0.14 μM, 0.28 μM, and 0.72 μM, respectively. [1] GDC-0941 treatment potently inhibits the proliferation of both trastuzumab-sensitive and -insensitive HER2-amplified cells with IC50 of 149-944 nM. GDC-0941 inhibits proliferation of HER2-amplified cells that harbor PIK3CA mutations with IC50 of <500 nM, and effectively inhibits both proliferation and viability of HER2-amplified breast cancer cells that are resistant to trastuzumab due to PTEN loss. [2] GDC-0941 significantly inhibits the growth of HCT116, DLD1 and HT29 cells with GI50 of 1081 nM, 1070 nM and 157 nM, respectively. [3] GDC-0941 inhibits tumor cell proliferation, induces apoptosis and suppresses centroblast population. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
Sf9M2fKdGtqdmG|ZTDBd5NigQ>?NHiyZ44yKGh?NVvBNoVoTE2VTx?=MmjqTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCmZXz0ZUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy|IHPv[ZhxemW|c3nu[{BxQDWjbIDoZUB4cXSqIFnDOVAhd2ZiMD6wNFMh|ryPM4LyTVE5PzV2NkW0
Sf9MUTLbY5ie2ViQYPzZZk>NEnqOVAyKGh?NHixSoRFVVORMkH1TY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCkZYThJGgyODR5LWKgcZV1[W62IHX4dJJme3OnZDDpckBU\jliY3XscJMh[2:neIDy[ZN{cW6pIIC4OYFteGijIIfpeIghUUN3MDDv[kAxNjByMzFOwG0>M1jW[VE5PzV2NkW0
Sf9NUjRXZhkU2mwYYPlJGF{e2G7MkLxNUBpMVLEUXNQMoOzTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCkZYThJGU2PDVvSzDteZRidnRiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{Bkd2W6cILld5NqdmdicEi1ZYxxcGFid3n0bEBKSzVyIH;mJFAvODB|IN88US=>NVHUT4V[OTh5NUS2OVQ>
Sf9MoTST4lv[XOnIFHzd4F6MYGxJIg>NVKzZ5QzTE2VTx?=NX3FfIRFUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQTVNMKHBzMUDi[ZRiKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZ49mgHC{ZYPzbY5oKHB6NXHsdIhiKHerdHigTWM2OCCxZjCwMlA{OyEQvF2=M4rmd|E5PzV2NkW0
Sf9MXvLbY5ie2ViQYPzZZk>NUTGbXVzOSCqNEn2UXFFVVORMV3Jcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1ugdFEyOGGucHjhJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiY3;lfJBz\XO|aX7nJJA5PWGucHjhNXe2enhSOTh5NUS2OVQ>
MDA-MB-361NEX0fJhHfW6ldHnvckBCe3OjeR?=MWmyJIg>M3TvdmROW09?NYPRenhVUW6qaXLpeIlwdiCxZjDBb5QhW2W{NEezJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDNSGEuVUJvM{[xJINmdGy|IIfpeIghWEmNM1PBJGU2PDVvSzDteZRifGmxbjD3bZRpKEmFNUCgc4YhOC5yMkig{txONVW2RWs2OTh5NUS2OVQ>
PC3NFG0dHZHfW6ldHnvckBCe3OjeR?=NFi4W5UzKGh?M4faSGROW09?MkPNTY5pcWKrdHnvckBw\iCDa4SgV4VzPDd|IIDoc5NxcG:{eXzheIlwdiCrbjDQWGVPNW63bHygbJVu[W5iUFOzJINmdGy|IIfpeIghUUN3MDDv[kAxNjB|NzFOwG0>MmLZNVg4PTR4NUS=
U87MGM1:0ZmZ2dmO2aX;uJGF{e2G7NGnk[JgzKGh?MlXqSG1UVw>?MV;Jcohq[mm2aX;uJI9nKEGtdDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIGDUSW4udnWubDDoeY1idiCXOEfNS{Bk\WyuczD3bZRpKEmFNUCgc4YhOC5yNE[g{txOMlz2NVg4PTR4NUS=
MDA-MB-361MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVLRTod1QTZiaB?=MmWySG1UVw>?NIKxSHlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1|NkGgZ4VtdHNid3n0bEBRUUt|Q1GgSVU1PS2NIH31eIF1cW:wIIfpeIghUUN3MDDv[kAxNjd{IN88US=>MnLHNVg4PTR4NUS=
A2780NGXJRo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;2PXk6PiCqMoj0SG1UVw>?M4HsXmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUK3PFAh[2WubIOge4l1cCCSSVuzR2Eh[W6mIGDUSW4hdXW2YYTpc44hf2m2aDDJR|UxKG:oIECuNVQh|ryPNWDRc5ZtOTh5NUS2OVQ>
PC3NXfPdohJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPrNXo6PiCqNETsWmFFVVORNXHsTWViUUN3ME2wMlI5KM7:TR?=NH7hXpgyQDd3NE[1OC=>
U87MGM2\T[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXOeG86PiCqMnziSG1UVw>?MWXJR|UxRTBwOUWg{txONVjSfpJyOTh5NUS2OVQ>
Sf9Ml60T4lv[XOnIFHzd4F6MoP2N|AhdWmwNE\oXJdFVVORNELRUpZKdmirYnn0bY9vKG:oIHj1cYFvKFCLM1vnZY1u[SCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgZY1wfW62IH;mJGFVWCClb37zeY1m\CC5aYToJGlEPTBib3[gNE4xPDJizszNMYWyNlU1QDN2Mh?=
RAW 264.7MlTnT4lv[XOnIFHzd4F6M4PN[FkxKG2rbh?=NXfYV491TE2VTx?=Mnr6TY5pcWKrdHnvckBw\iCqdX3hckBRUTONZ3HtcYEh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhSUuWIIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4zQThizszNNVnXfI9{OjJ3NEizOFI>
Sf9NE\OelBMcW6jc3WgRZN{[Xl?MmXUNUBpMmDUTY5pcWKrdHnvckBw\iCJU2St[pV{\WRiaIXtZY4hemWlb33ibY5idnRiUFmzT4JmfGFiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOIOTDj[YxteyC5aYToJGlEPTBib3[gNE4xOTdizszNNUjW[4lUOjN3NEC2OFU>
Sf9MYTLbY5ie2ViQYPzZZk>MVmxJIg>NFrRUlRKdmirYnn0bY9vKG:oIFfTWE1nfXOnZDDoeY1idiC{ZXPvcYJqdmGwdDDQTVNM\GWudHGg[ZhxemW|c3XkNVTwSpZbOjN3NEC2OFU>
Sf9MlK2T4lv[XOnIFHzd4F6MYexJIg>M1rTN2lvcGmkaYTpc44hd2ZiR2PUMYZ2e2WmIHj1cYFvKHKnY3;tZolv[W62IGDJN2to[W2vYTDlfJBz\XO|ZXS=NGrYU4szOzV2ME[0OS=>
Sf9NUHnOmV{U2mwYYPlJGF{e2G7NYPRUXVWOSCqNF7kSHhKdmirYnn0bY9vKG:oIFfTWE1nfXOnZDDoeY1idiC{ZXPvcYJqdmGwdDDQTVNM[WyyaHGg[ZhxemW|c3XkMkTXNlM2PDB4NEW=
SKOV3Mm\nT4lv[XOnIFHzd4F6NIjISZoyKM7:TR?=NVns[IJ4OSCqNILVWoNFVVORNWHaNnJKUW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDBb5QhW2W{NEezJJBpd3OyaH;yfYxifGmxbh?=NEWy[YQzOzN4MEO0PC=>
MCF7M2nE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWryWYp1OSEQvF2=M4rlOlk3KGh?Ml\nSG1UVw>?NXH0TZg3T0l3ME2wMlA4ODJizszNMXiyN|M3ODN2OB?=
SKOV3MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXfufVdjOSEQvF2=MUO5OkBpM{fHTmROW09?M4nvO2dKPTB;MD6xOFc3KM7:TR?=NFLSblUzOzN4MEO0PC=>
PC3NIr4WohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX23NkBpMke1SG1UVw>?M{TxU2lEPTB;MD6yPEDPxE1?M2LUb|IyQThzN{G0
MCF7.1NHvmbodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzxO|IhcA>?NIfkVZNFVVORM3;jdmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{4yKGOnbHzzJIV5eHKnc4PpcochUEWUMjDn[Y5mKHerdHigTWM2OCCxZjCwMlI5KM7:TR?=MYOyNVk5OTdzNB?=
MCF7-neo/Her2MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XSR|czKGh?Mo[xSG1UVw>?NIjXV4dKSzVyPUCuNlkh|ryPMXGyN|Y3OjlyMx?=
MCF7-neo/Her2NFviUGRMcW6jc3WgRZN{[Xl?MkTyTY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKEGNVDDwbI9{eGixconsZZRqd25iYYSgV|Q4OyC5aYToJGlEPTBib3[gNE4xODdizszNNEjiUYgzOzZ4MkmwNy=>
PC3Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1u3XlczKGh?M32zb2ROW09?NYPjN3Z5TUN3ME2wMlM1KM7:TR?=NHqzUmkzOTl6NU[zPS=>
MCF7.1MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmfyO|IhcA>?M4HXfWROW09?Mn7ERY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPQ1[3MlEh[2WubIOg[ZhxemW|c3nu[{BRUTONYXzwbIEhdXW2YX70JJdqfGhiRVO1NEBw\iByLkO5JO69VQ>?MVyyNVk5PTZ|OR?=
PC3NWH5OmY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4K0V|czKGh?NY\uXIxNTE2VTx?=NV7uRZpRSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOg[IVncWOrZX70JIlvKFCWRV6ge4l1cCCLQ{WwJI9nKDBwM{mg{txOMY[yNFA2ODZ4OR?=
MCF7.1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInsWI44OiCqM2i5dWROW09?NHPaOHVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlcvOSClZXzsd{BmgHC{ZYPzbY5oKFCLM1vhcJBp[SCvdYThcpQhf2m2aDDJR|UxKG:oIECuN|Qh|ryPNXnIRnlwOjByNUC2Olk>
MCF7.1M33MXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITkclc4OiCqMV7FR|UxRTBwN{Kg{txONHHPbIIzODN2Nk[1Oi=>
NCI-H1975Ml7TR5l1d3SxeHnjJGF{e2G7M13KeFczKGh?MYjJR|UxRTBwMkeg{txOMYiyN|A2QTV2NR?=
H460NE\id|dEgXSxdH;4bYMhSXO|YYm=Mo\GO|IhcA>?M1HyVGlEPTB;MD64O{DPxE1?M3S2XVI{ODV7NUS1
HT-29NVXRNYdvS3m2b4TvfIlkKEG|c3H5MmXSO|IhcA>?MVjJR|UxRTBwNk[g{txOM{e5OlI{ODV7NUS1
HepG2M3rRcGN6fG:2b4jpZ{BCe3OjeR?=MYS3NkBpNVrRVVduUUN3ME2xJO69VQ>?M2fLR|I{ODV7NUS1
SGC7901MnrUR5l1d3SxeHnjJGF{e2G7M2XsXVczKGh?NIG2c|hKSzVyPUGuPEDPxE1?M{\Pc|I{ODV7NUS1
NCI-H226MYjDfZRwfG:6aXOgRZN{[Xl?MnHrO|IhcA>?M1y3RWlEPTB;Mj65JO69VQ>?MWSyN|A2QTV2NR?=
A549MmP1R5l1d3SxeHnjJGF{e2G7MUm3NkBpMUDJR|UxRTZwOTFOwG0>MXqyN|A2QTV2NR?=
U87MGMWrDfZRwfG:6aXOgRZN{[Xl?M4DpOFczKGh?MkHLTWM2OD15Lke3JO69VQ>?MXWyN|A2QTV2NR?=
HBC4Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTsc4dIUTVyPT22MlA{KE1?M2XXbVIzOzN4MkS2
BSY1MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkXocI9oT0l3ME2tOk46OCCPNWHyUpNUOjJ|M{[yOFY>
HBC5M{D0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTidllldG:pR1m1NF0uPi54MDDNM{PtO|IzOzN4MkS2
MCF7NVP5b2lKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUn6WlZwdG:pR1m1NF0uPy5|MzDNM4LOSlIzOzN4MkS2
MDA-MB-231MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXL4Nok{dG:pR1m1NF0uPS52NjDNMUSyNlM{PjJ2Nh?=
U251MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHhcI9oT0l3ME2tOU42OCCPNX31RWxTOjJ|M{[yOFY>
SF268MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfsc4dIUTVyPT21MlM6KE1?NFXVdGkzOjN|NkK0Oi=>
SF295NHvqT2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;mcI9oT0l3ME2tOk4{PyCPNEHrOoQzOjN|NkK0Oi=>
SF539NWLtepVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mne1cI9oT0l3ME2tOk42OCCPNHHKXFAzOjN|NkK0Oi=>
SNB75M{fQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4nvSoxw\0eLNUC9MVcvOTBiTR?=MWSyNlM{PjJ2Nh?=
SNB78Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYPqbpVndG:pR1m1NF0uPi53MjDNNF76PHQzOjN|NkK0Oi=>
HCC2998NVfFO|ZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUHwW2hqdG:pR1m1NF0uPi5{OTDNM{W2T|IzOzN4MkS2
KM12M2P1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnsc4dIUTVyPT21Mlc3KE1?NUfqZpp7OjJ|M{[yOFY>
HT-29NHfKNWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIfrPHJtd2eJSUWwQU03NjNyIF2=MkXuNlI{OzZ{NE[=
HCT15MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrOSGdNdG:pR1m1NF0uPi5zMjDNMX2yNlM{PjJ2Nh?=
HCT116M3W2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\4d|Vtd2eJSUWwQU02Njh5IF2=NHrjTnMzOjN|NkK0Oi=>
NCI-H23NEO1ZWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGPU[5Rtd2eJSUWwQU02Njd|IF2=MoLiNlI{OzZ{NE[=
NCI-H226MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV73fW9odG:pR1m1NF0uPi5{MTDNNG[4[XMzOjN|NkK0Oi=>
NCI-H522MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUTQ[pFpdG:pR1m1NF0uPi53ODDNMV2yNlM{PjJ2Nh?=
NCI-H483NWXyeYZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;3ZnFPdG:pR1m1NF0uPi53NjDNNXfZOXdMOjJ|M{[yOFY>
A549NXTER2VNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LTb4xw\0eLNUC9MVYvOTViTR?=M1KyXlIzOzN4MkS2
DMS273M3jqZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTsc4dIUTVyPT22MlQ{KE1?MUKyNlM{PjJ2Nh?=
DMS114M2LMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH;FdWRtd2eJSUWwQU02Njl{IF2=MkPaNlI{OzZ{NE[=
LOXIMVIMnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfsc4dIUTVyPT22MlI6KE1?MnWzNlI{OzZ{NE[=
OVCAR3NFzQTotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4PFb4xw\0eLNUC9MVYvPzFiTR?=MmXUNlI{OzZ{NE[=
OVCAR4M2jvWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTJeFlGdG:pR1m1NF0uPS55NjDNNYfBUWR5OjJ|M{[yOFY>
OVCAR5M2DKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLrWpZtd2eJSUWwQU03NjJ4IF2=MX6yNlM{PjJ2Nh?=
OVCAR8MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{DIT4xw\0eLNUC9MVUvPzNiTR?=MVmyNlM{PjJ2Nh?=
SKOV3MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTqeZh5dG:pR1m1NF0uPi53MjDNMmfRNlI{OzZ{NE[=
RXF631LMnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{S2S4xw\0eLNUC9MVYvQDhiTR?=M{\hUVIzOzN4MkS2
ACHNMnnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnsc4dIUTVyPT22MlA4KE1?NEHWdWgzOjN|NkK0Oi=>
St-4MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjsc4dIUTVyPT21MlU3KE1?MmTYNlI{OzZ{NE[=
MKN1NHjEc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXsc4dIUTVyPT23MlA5KE1?MUeyNlM{PjJ2Nh?=
MKN7NGDEXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\3SWFtd2eJSUWwQU03NjVyIF2=MoPONlI{OzZ{NE[=
MKN28MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnhcI9oT0l3ME2tOU42OiCPM{K4TVIzOzN4MkS2
MKN45NH31SmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUDFTo9MdG:pR1m1NF0uPi53NTDNNV[xfFNMOjJ|M{[yOFY>
MKN74MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\3cIxw\0eLNUC9MVYvODJiTR?=MoTVNlI{OzZ{NE[=
DU145NHLDWmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rxZYxw\0eLNUC9MVUvQDViTR?=NFXlS|YzOjN|NkK0Oi=>
PC3M3;ob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF7uT|htd2eJSUWwQU03NjZ4IF2=NXLlPJc6OjJ|M{[yOFY>
ES5M3rLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17XNWlEPTB;NUCuNlEhdk1?M4DkSHNCVkeHUh?=
HHNYrZWmxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vpdGlEPTB;MUGxMlA5KG6PNUPqZ4tvW0GQR1XS
MHH-PREB-1NUHSUWFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfyVmNTUUN3ME2xNVQvOyCwTR?=NWHQNJhsW0GQR1XS
NCI-H1770NYG1fHJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2\qcWlEPTB;MUKzMlg3KG6PMmOzV2FPT0WU
HuO9NYPOW|hwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrvPWhKSzVyPUKwOk4xOiCwTR?=NGm3Vo5USU6JRWK=
HAL-01NVXjb4gzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnu4TWM2OD1{ME[uO|Mhdk1?MXvTRW5ITVJ?
NOS-1Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3Lv[2lEPTB;MkGxMlgzKG6PMmnpV2FPT0WU
HGC-27MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTJzMj61O{BvVQ>?MULTRW5ITVJ?
NB69NGnSRldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPYTWM2OD1{NEWuNlchdk1?MlzsV2FPT0WU
RS4-11M1LLOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3CU3NRUUN3ME2yOlEvPzZibl2=MkPwV2FPT0WU
DOKMmDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mle4TWM2OD1|MEGuO{BvVQ>?NGrsXoxUSU6JRWK=
LB2241-RCCNIrSZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTNyMz64OEBvVQ>?MkS1V2FPT0WU
NCI-H1623NHLqTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jBXGlEPTB;M{C0MlA5KG6PMlX5V2FPT0WU
YH-13NHe1[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEHjVINKSzVyPUOwOE4{OiCwTR?=Mn76V2FPT0WU
BPH-1MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjDPJYxUUN3ME2zNVQhdk1?MYHTRW5ITVJ?
AN3-CANXrscFlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWrVPYJIUUN3ME2zOFAvOzdibl2=MnL2V2FPT0WU
ES7NUPac2hDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVvS[|JDUUN3ME2zOFEvQTlibl2=MoDhV2FPT0WU
MDA-MB-175-VIIM2ewXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmG3TWM2OD1|NUKuPVIhdk1?Mn\HV2FPT0WU
GAMGM4\uZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYnRT2VHUUN3ME2zO|AvQDVibl2=NHTCSZVUSU6JRWK=
CHL-1MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXITWM2OD1|N{iuOlUhdk1?NYTmfXpRW0GQR1XS
NB7NYnQNZgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnXuTWM2OD1|OEmuPFMhdk1?NHrScmNUSU6JRWK=
MFE-280MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEP6eWtKSzVyPUSxPE4zKG6PMmXVV2FPT0WU
HL-60MnTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlnYTWM2OD12MkWuO|Uhdk1?NIrLOppUSU6JRWK=
GCIYMmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkLoTWM2OD12M{OuPEBvVQ>?NUWzfoJIW0GQR1XS
MDA-MB-361M1zMS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXrJR|UxRTR|OT6xN{BvVQ>?NXfrRVZ2W0GQR1XS
LXF-289NF[0XmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoLXTWM2OD12NEiuNlchdk1?MUHTRW5ITVJ?
NBsusSRNFTSfG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEP4O3JKSzVyPUS4PE45PSCwTR?=MXTTRW5ITVJ?
KU-19-19MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jaPGlEPTB;NUG2MlA4KG6PNXqwNng{W0GQR1XS
A204MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2W3dmlEPTB;NUKyMlM{KG6PM2HBWHNCVkeHUh?=
LB1047-RCCM{jRc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1X6fGlEPTB;NUKyMlk{KG6PNY\1NodOW0GQR1XS
COLO-684NXjvTFFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrLXpFKUUN3ME21NlMvOTFibl2=MkLtV2FPT0WU
PA-1NHvkN|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTV|Mj60NUBvVQ>?NF63SWVUSU6JRWK=
MG-63MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVzhflY2UUN3ME21OFEvOTFibl2=NHn6SXRUSU6JRWK=
BHT-101M3r6Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnrxTWM2OD13NESuPVQhdk1?MUfTRW5ITVJ?
NKM-1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnHRTWM2OD13OUOuNFkhdk1?M3:wRnNCVkeHUh?=
T47DMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;OS2lEPTB;NUm3MlU3KG6PM4PRO3NCVkeHUh?=
MOLT-4MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2PTc2lEPTB;NkKzMlYzKG6PNULJelBDW0GQR1XS
IGROV-1M1T6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPhdlhKSzVyPU[zOE4{OSCwTR?=MUnTRW5ITVJ?
ES4NYrwfoFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV;JR|UxRTZ|OT61OEBvVQ>?MUDTRW5ITVJ?
HuO-3N1MoPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTZ2Mj6zPEBvVQ>?NH3tPFVUSU6JRWK=
NEC8NWP2O5Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUDmbIhMUUN3ME22OVMvPTdibl2=MYPTRW5ITVJ?
HO-1-N-1NGPPZnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILJXppKSzVyPU[1PU4yPyCwTR?=M{TZUHNCVkeHUh?=
EPCL-272HMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHjHPVJKSzVyPU[4O{4zOSCwTR?=MUHTRW5ITVJ?
D-263MGNVzQd|BsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MljSTWM2OD15MUiuNUBvVQ>?NFi1[WFUSU6JRWK=
MV-4-11M37HOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTd{ND6zNUBvVQ>?NX7wOG5rW0GQR1XS
SK-NEP-1M4\OOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7oTWM2OD15MkWuPVQhdk1?MnjZV2FPT0WU
SW872M2r1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUCzfXVyUUN3ME23NlcvQDlibl2=MYPTRW5ITVJ?
P30-OHKMl[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml7kTWM2OD15M{CuO|Ehdk1?Ml25V2FPT0WU
OMC-1MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTd3MT6wPUBvVQ>?NIWyb5lUSU6JRWK=
LoVoNFXxOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLzXWFKSzVyPUe3O{46KG6PNWTVUpZ3W0GQR1XS
LNCaP-Clone-FGCMn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkL5TWM2OD15OU[uN|Qhdk1?NH7QdVVUSU6JRWK=
L-363NIDzUlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTITWM2OD15OUiuOFIhdk1?MWrTRW5ITVJ?
ES8MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmrpTWM2OD16MUCuOVIhdk1?MlvJV2FPT0WU
697MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLWdYhKSzVyPUizNU42PSCwTR?=M4\zTHNCVkeHUh?=
HSC-3M3f3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3jC[WlEPTB;OEO5MlU1KG6PNUDoRVJMW0GQR1XS
H4NEnLc2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYnWSJBCUUN3ME24OVAvQDVibl2=NHzjV2NUSU6JRWK=
QIMR-WILMoq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHG1OWNKSzVyPUi2OU4zKG6PMVXTRW5ITVJ?
OAW-42MkfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml3mTWM2OD16N{KuNVkhdk1?M3i3OHNCVkeHUh?=
MCF7MnjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF;wb2RKSzVyPUi5PE42QSCwTR?=NH7OfJBUSU6JRWK=
SCC-25Mn31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PXT2lEPTB;OUG0MlE6KG6PMXjTRW5ITVJ?
NCI-H1563MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYj3c|E5UUN3ME25NVUvQTlibl2=MoDQV2FPT0WU
OVCAR-5NXfyUpBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTl2MD6xO{BvVQ>?MYfTRW5ITVJ?
HDLM-2NI\KbWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGrzbHNKSzVyPUm0PU4zKG6PMXjTRW5ITVJ?
NB5MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmfITWM2OD17NU[uOkBvVQ>?MlPvV2FPT0WU
NCI-H292NEXzdWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkCyTWM2OD17N{SuN|Ihdk1?MYXTRW5ITVJ?
A101DM4jkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\4TWM2OD17OUCuNVkhdk1?MlHEV2FPT0WU
NCI-H1648MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYrXZotXUUN3ME25PVgvPTFibl2=NHnhVoRUSU6JRWK=
EKVXMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWHLeZRGUUN3ME2xMlAyOjlizszNMX;TRW5ITVJ?
SW1710NF2zd3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17EZWlEPTB;MT6wOFI{OyEQvF2=MmP4V2FPT0WU
WM-115MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVG4OYxRUUN3ME2xMlA3PjV4IN88US=>MmiyV2FPT0WU
CAL-54NFHFb2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEn5W4JKSzVyPUGuNFcxQDFizszNNFnE[VNUSU6JRWK=
TGBC24TKBMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTFwMEiwOFUh|ryPM4fienNCVkeHUh?=
NCI-H520M2PLbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTFwMEi5Olch|ryPM2DMRnNCVkeHUh?=
D-423MGMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHFfYNKSzVyPUGuNFk6PjJizszNM1exSXNCVkeHUh?=
BFTC-905M2P5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXLMbnBSUUN3ME2xMlE{PDR7IN88US=>MUDTRW5ITVJ?
HTNGjmSnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmHOTWM2OD1zLkGzOFc5KM7:TR?=NWTxbXMzW0GQR1XS
CTB-1MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrlV5NKSzVyPUGuNVQzQTNizszNM3HlTXNCVkeHUh?=
Hs-578-TMn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LUVGlEPTB;MT6xPVU3PSEQvF2=MmTuV2FPT0WU
HuH-7NVm2e2xDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXmTWM2OD1zLkKwPVQ6KM7:TR?=NEHFNWRUSU6JRWK=
LB996-RCCNF7jZ|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTFwMkKxO|ch|ryPMVrTRW5ITVJ?
KYSE-270MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV32V2V6UUN3ME2xMlI6PzN2IN88US=>NU\scoR2W0GQR1XS
A4-FukNX22T2EyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTFwMkm5PVMh|ryPM4PONHNCVkeHUh?=
A498M37aTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml63TWM2OD1zLkOwOFc1KM7:TR?=NVzqUHcxW0GQR1XS
SK-MEL-1Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TKRWlEPTB;MT6zNFY4QSEQvF2=MnLTV2FPT0WU
AU565NETJbJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTFwM{G4OlMh|ryPM1rSOHNCVkeHUh?=
Saos-2M1faSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXzDZmo5UUN3ME2xMlM{OjB3IN88US=>MVvTRW5ITVJ?
A549NGLu[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVPJR|UxRTFwM{m5O{DPxE1?NVXWWHFsW0GQR1XS
BFTC-909MlLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnr0TWM2OD1zLkSzN|A2KM7:TR?=MWLTRW5ITVJ?
MDA-MB-415NYfVSnRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlr1TWM2OD1zLkS4OlkzKM7:TR?=NIXh[VVUSU6JRWK=
639-VNWS3OnV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlLCTWM2OD1zLkWwNlQ2KM7:TR?=M{XkOHNCVkeHUh?=
A704MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfJTWM2OD1zLkWwO|g2KM7:TR?=MlHXV2FPT0WU
PANC-03-27Ml;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVzLTIp2UUN3ME2xMlUyPDB6IN88US=>NHTudpBUSU6JRWK=
SK-MEL-28NYfEeGN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlrLTWM2OD1zLkW2NFg2KM7:TR?=NWK5Z2d1W0GQR1XS
Ramos-2G6-4C10NVv6SYdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3PxcmlEPTB;MT62NFc1PiEQvF2=M{\2d3NCVkeHUh?=
HuP-T4NVnQOFZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2rVeGlEPTB;MT62NFc4QCEQvF2=NVuwbnV4W0GQR1XS
VA-ES-BJNXHseWQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DnbmlEPTB;MT62NVI4KM7:TR?=MWfTRW5ITVJ?
EFM-19MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYnJR|UxRTFwNkG4NUDPxE1?M17CZnNCVkeHUh?=
G-401NFP2fZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rRNmlEPTB;MT62NlE3PCEQvF2=MlzTV2FPT0WU
D-566MGM{HwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFPme5NKSzVyPUGuOlI2OyEQvF2=M2fMSnNCVkeHUh?=
JVM-3NUK0NWVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHjnfIdKSzVyPUGuOlQ5PzVizszNMmPiV2FPT0WU
TK10MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX7FOW9SUUN3ME2xMlY4ODh|IN88US=>NWG5RnJ2W0GQR1XS
BT-20MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTFwNki5NFIh|ryPMof6V2FPT0WU
EGI-1Mo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1PlcWlEPTB;MT64OFcxOSEQvF2=NUX4bnFMW0GQR1XS
EW-16M3rac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlzoTWM2OD1zLki1NVgzKM7:TR?=NW\SboZKW0GQR1XS
NCI-H2228MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{HBb2lEPTB;MT64OVIxOyEQvF2=MYXTRW5ITVJ?
BB49-HNCMkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUW4U2FQUUN3ME2xMlg5Pjl{IN88US=>M2fGVHNCVkeHUh?=
G-402NIr6ZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfTclVHUUN3ME2xMlg6Pzl5IN88US=>M1fMPHNCVkeHUh?=
NCI-H526MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;5d2lEPTB;MT65NVM6KM7:TR?=MoXsV2FPT0WU
ME-180MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\hW|g{UUN3ME2xMlk{PDd5IN88US=>MV;TRW5ITVJ?
PFSK-1NGftW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NULWfVE3UUN3ME2xMlk1PDV6IN88US=>Moj6V2FPT0WU
TYK-nuMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\CTWM2OD1zLkm1PFI{KM7:TR?=M1TBUXNCVkeHUh?=
HOSM4nXeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7rTWM2OD1zLkm3PVQ5KM7:TR?=MmfsV2FPT0WU
T98GNXnhRYdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmX2TWM2OD1zLkm5NFA3KM7:TR?=M3mwXnNCVkeHUh?=
SK-MES-1NVHIdWc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTJwMEGzN|Ih|ryPNYjFdpE1W0GQR1XS
SNB75NWjFbohWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmTXTWM2OD1{LkCxOVQyKM7:TR?=Ml3UV2FPT0WU
LAMA-84MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7FfZNLUUN3ME2yMlAzPjh7IN88US=>M2juVHNCVkeHUh?=
CAL-39MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXm2dnc4UUN3ME2yMlA{OjhizszNM2\Oe3NCVkeHUh?=
LOXIMVIMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnNT4xbUUN3ME2yMlA1ODh2IN88US=>NHna[4JUSU6JRWK=
NH-12MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;H[WlEPTB;Mj6wOVQzPCEQvF2=MoTPV2FPT0WU
NCI-H1048NHLHc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\wWGlEPTB;Mj6xNFUzKM7:TR?=NGjXfGNUSU6JRWK=
KS-1MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTJwMUGwNFEh|ryPNIrPV|VUSU6JRWK=
NCI-N87MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGnTRXhKSzVyPUKuNVM{QDRizszNM4HrfnNCVkeHUh?=
CHP-212MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUi5OHplUUN3ME2yMlE5PDR{IN88US=>NIPrVHhUSU6JRWK=
HCC1419MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLnTWM2OD1{LkKxNVE2KM7:TR?=MlSwV2FPT0WU
ES1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{TSV2lEPTB;Mj6yNVMzPiEQvF2=MWrTRW5ITVJ?
NCI-H2030NV:0c2JrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTJwMkSxNlMh|ryPMWTTRW5ITVJ?
EW-22NEeyfIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoSwTWM2OD1{LkK1NFY4KM7:TR?=M2r3fXNCVkeHUh?=
A431M3vHb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3TNXmlEPTB;Mj6yO|M2PCEQvF2=M3\mZnNCVkeHUh?=
SF126M3m2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkD3TWM2OD1{LkOwOlI2KM7:TR?=NYfvVJNDW0GQR1XS
SF295NFzzWWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTCTWM2OD1{LkOxOVI1KM7:TR?=MmLmV2FPT0WU
D-502MGMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIWwephKSzVyPUKuN|I1PjFizszNMYDTRW5ITVJ?
HCC2157NX3QNYV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTJwM{K5Nlch|ryPMkn1V2FPT0WU
D-283MEDMljOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{TZd2lEPTB;Mj6zOVkzPiEQvF2=M3izdXNCVkeHUh?=
SNU-423M3G3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmfRTWM2OD1{LkSwNVcyKM7:TR?=M{fGTnNCVkeHUh?=
SK-LU-1NYPvfXlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY\ZWXFCUUN3ME2yMlQ1PTh4IN88US=>MnzHV2FPT0WU
22RV1NHHHOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfoW5NDUUN3ME2yMlQ2PjF5IN88US=>MYXTRW5ITVJ?
SW1088NFuwc2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mkm2TWM2OD1{LkS5NlE{KM7:TR?=NELNXGVUSU6JRWK=
HT-3NXnqeZJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrtV3N[UUN3ME2yMlQ6OjV7IN88US=>M{X3NXNCVkeHUh?=
NCI-H1666NWnXVll[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1i2UGlEPTB;Mj61NVExPCEQvF2=MX;TRW5ITVJ?
EM-2MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXnReJBOUUN3ME2yMlUyOTZ7IN88US=>MWjTRW5ITVJ?
SNU-449M4\2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWXp[3oyUUN3ME2yMlU4ODF2IN88US=>MoTYV2FPT0WU
786-0NHnjbVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm\QTWM2OD1{LkW5NlM5KM7:TR?=MU\TRW5ITVJ?
SKG-IIIaM{HiV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3\DfWlEPTB;Mj62OVk{QSEQvF2=MmnPV2FPT0WU
MEL-HOMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{i2cGlEPTB;Mj62O|Y{PCEQvF2=M3TIWnNCVkeHUh?=
LCLC-97TM1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWi0[VdHUUN3ME2yMlY6OjZ5IN88US=>MkLrV2FPT0WU
MKN7NHixUlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInJfFVKSzVyPUKuO|A4PTRizszNMY\TRW5ITVJ?
5637MoDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGD1WVFKSzVyPUKuO|ExOzVizszNMWjTRW5ITVJ?
HOP-92MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M120cGlEPTB;Mj63OFcyPyEQvF2=M4PTbnNCVkeHUh?=
MDA-MB-157Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjvZ4VGUUN3ME2yMlgzODJ|IN88US=>NFz3S2dUSU6JRWK=
NB12NXTYXGtDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHnJXWdKSzVyPUKuPFQ6OTRizszNNWXueIpWW0GQR1XS
DMS-273M3XHSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnzZ3duUUN3ME2yMlg3PDdizszNMUnTRW5ITVJ?
HCC70M1zlVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPIb3hKSzVyPUKuPFY2QDlizszNMkTkV2FPT0WU
YKG-1MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4TxU2lEPTB;Mz6wN|c5PyEQvF2=NXiwcVQ4W0GQR1XS
NCI-H28NH3sbpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW\1T2RlUUN3ME2zMlA2OjlzIN88US=>MoPRV2FPT0WU
HNM4i4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1rhSmlEPTB;Mz6wOlY{PiEQvF2=NImwVoVUSU6JRWK=
HT-1080M1nYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnK1TWM2OD1|LkC4OlA3KM7:TR?=M37QcXNCVkeHUh?=
HPAF-IIM1m3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUPOeYhyUUN3ME2zMlExODZ6IN88US=>NWPvOFFYW0GQR1XS
U-2-OSMlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPuRVZKSzVyPUOuNVM4QDJizszNMkjsV2FPT0WU
SNU-387Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;ZbHlLUUN3ME2zMlE3OzZ2IN88US=>Ml;WV2FPT0WU
BeckerNVrISIhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGWwTHdKSzVyPUOuNVY5ODhizszNNXXs[4xoW0GQR1XS
BHYNE\IcGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVPjdYFKUUN3ME2zMlI2PTdzIN88US=>M2rZZXNCVkeHUh?=
HTC-C3MmLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWDSXVBlUUN3ME2zMlI6OzV{IN88US=>MoTvV2FPT0WU
M14Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfRe4hKSzVyPUOuN|A3PjNizszNMlfXV2FPT0WU
COR-L23NYDm[GpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M37oWGlEPTB;Mz6zO|I4QSEQvF2=NHjCcHNUSU6JRWK=
C32NEDMPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\0eI9xUUN3ME2zMlQyPTB6IN88US=>NX60fHNTW0GQR1XS
MewoNY\SdYVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTNwNEKxPFIh|ryPNF\FXXpUSU6JRWK=
TE-8MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTNwNEiyOVkh|ryPMkHOV2FPT0WU
RPMI-2650NFX4NVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFX0R|ZKSzVyPUOuOlA3OzdizszNNVW3O2JJW0GQR1XS
AGSNX3FdohST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;ETWM2OD1|Lk[yOFY1KM7:TR?=MojwV2FPT0WU
MZ2-MELNEfIfGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnvRTWM2OD1|Lk[2NVM5KM7:TR?=MmfKV2FPT0WU
Calu-3MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWW0VpNPUUN3ME2zMlcyOjh5IN88US=>NHfsblFUSU6JRWK=
SJSA-1MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjTWoFwUUN3ME2zMlcyOzF3IN88US=>Mo\TV2FPT0WU
SW962MnG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH3GdIVKSzVyPUOuO|I3OzZizszNMWfTRW5ITVJ?
PC-14NH3kU4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2fNeGlEPTB;Mz63N|IzOiEQvF2=MXXTRW5ITVJ?
SW1573MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTNwN{WzOFgh|ryPMXnTRW5ITVJ?
769-PMmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTNwOEK3OFMh|ryPMWXTRW5ITVJ?
KNS-62MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFe3[25KSzVyPUOuPVI{OzhizszNMnOyV2FPT0WU
NCI-H747NH63WJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVfLSlZHUUN3ME20MlA2PjN6IN88US=>M3vP[XNCVkeHUh?=
LN-405MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTRwMUW3Nlgh|ryPMVfTRW5ITVJ?
OVCAR-8MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTRwMkK1OFMh|ryPMnWxV2FPT0WU
DMS-114NWjleppxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHvNdZpKSzVyPUSuNlM5QTFizszNMUjTRW5ITVJ?
NCI-H2126NULZPIJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFf4VplKSzVyPUSuNlQ2PThizszNMVTTRW5ITVJ?
TCCSUPMlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTRwMkS3PFgh|ryPMXfTRW5ITVJ?
SK-N-FINYLuflJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{PHfWlEPTB;ND6yOVM{OiEQvF2=M4C2V3NCVkeHUh?=
HCE-4MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTRwMkexPVch|ryPNV7nOXBlW0GQR1XS
DK-MGM2Lt[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlP6TWM2OD12LkOwN|kh|ryPNYLa[oFYW0GQR1XS
RO82-W-1NVHXPJduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTRwM{K1PFQh|ryPM3K2V3NCVkeHUh?=
A2780NH3zSZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MojNTWM2OD12LkO2OlgzKM7:TR?=NV3YPHpwW0GQR1XS
ETK-1NWDIVYZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW\MNIZKUUN3ME20MlM4ODV{IN88US=>NGPHeZBUSU6JRWK=
FADUNYDEfFVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzISVRDUUN3ME20MlM4PDZ5IN88US=>M2G0c3NCVkeHUh?=
CAL-12TNVfRWVFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTRwNEG0NVMh|ryPNXr0doxjW0GQR1XS
647-VM{\iSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGXoV5ZKSzVyPUSuOFQxOjJizszNMkfnV2FPT0WU
TGBC1TKBMoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWGySJJZUUN3ME20MlQ2OTF|IN88US=>NG\Rd5dUSU6JRWK=
LU-99AM3LIV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUL5fWlHUUN3ME20MlQ3ODZizszNNGrrNVBUSU6JRWK=
CAL-33MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jiO2lEPTB;ND61NlQ2PiEQvF2=MYfTRW5ITVJ?
LU-134-AMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MonKTWM2OD12LkWyO|Q2KM7:TR?=NVzCbIU6W0GQR1XS
NCI-H1355M1jvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1Li[WlEPTB;ND61OVE1PiEQvF2=NYDwUldCW0GQR1XS
RPMI-7951MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHzLbpBKSzVyPUSuOVcxODJizszNMYjTRW5ITVJ?
TE-1MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV;JR|UxRTRwNk[xOFMh|ryPNV;BWm5IW0GQR1XS
OE33NIfzdYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XBcGlEPTB;ND63NFUyOSEQvF2=NV7EeZh{W0GQR1XS
CAL-51NGmzVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoDNTWM2OD12LkexNFgzKM7:TR?=MnHzV2FPT0WU
SW1783M1vkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVv4WI9KUUN3ME20Mlc2OzB6IN88US=>NYLoSWk1W0GQR1XS
BT-474NVjQbJdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXTTWM2OD12Lke2N|g1KM7:TR?=MlKxV2FPT0WU
KYSE-520M2q1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTRwOEezPVIh|ryPNYTjVJZbW0GQR1XS
8-MG-BAMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jEXGlEPTB;ND64PFU2PyEQvF2=NEXjfFFUSU6JRWK=
IA-LMM4jBbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkC1TWM2OD12Lkm5OFM2KM7:TR?=NF3ocHpUSU6JRWK=
SW954NFjkTmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVPJR|UxRTRwOUm0OFMh|ryPM4H4XXNCVkeHUh?=
RPMI-8226NXLZSll6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkC1TWM2OD13LkC1OFYyKM7:TR?=NWjReYQ{W0GQR1XS
MKN1MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYf3NWprUUN3ME21MlA4QTJ5IN88US=>MYTTRW5ITVJ?
A375M16xTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDXTWM2OD13LkC5NlU3KM7:TR?=NVS0VWZiW0GQR1XS
8305CNHni[G1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnBNZVKSzVyPUWuNFk5QDdizszNMoTvV2FPT0WU
CAL-62M37lfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV\TdGFFUUN3ME21MlE5OjV7IN88US=>MkP6V2FPT0WU
NB10NGHLblZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEK5coJKSzVyPUWuNlI4PDRizszNM3HNbXNCVkeHUh?=
OC-314MlfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTVwM{e0OFQh|ryPMYfTRW5ITVJ?
PSN1MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4HxcmlEPTB;NT6zPFI5PiEQvF2=M1:1TXNCVkeHUh?=
GR-STNFu2OpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfJdWtGUUN3ME21MlM5OzJ{IN88US=>NFz0WodUSU6JRWK=
P12-ICHIKAWAM1z0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;QTWM2OD13LkSwNUDPxE1?MmXFV2FPT0WU
NCI-H1092M1HWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTVwNEGxOFgh|ryPNHvCVppUSU6JRWK=
SCC-4NX3FO2JHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEW3NmRKSzVyPUWuOFE{PTVizszNNXeyc4hqW0GQR1XS
TE-6M4DLemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3qzS2lEPTB;NT60NVgyPiEQvF2=Mkj4V2FPT0WU
DOHH-2MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYG3UHhGUUN3ME21MlQzOjR6IN88US=>Mo\zV2FPT0WU
SW684MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTOdIhYUUN3ME21MlY3Ozh3IN88US=>M1TnTXNCVkeHUh?=
CP50-MEL-BMmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTVwNki2PFQh|ryPM17FcHNCVkeHUh?=
UM-UC-3NIPVZ|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHq0eJFKSzVyPUWuO|IzOzFizszNMoLVV2FPT0WU
LC-2-adNEm0bIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW[yPYVEUUN3ME21Mlc5OjVzIN88US=>MW\TRW5ITVJ?
PC-3NH3aW|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\PUGlEPTB;NT65NVYyPSEQvF2=M3HjOXNCVkeHUh?=
CANM4nBfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTVwOUK4NkDPxE1?MYjTRW5ITVJ?
ESS-1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn;NTWM2OD13Lkm3PFY6KM7:TR?=NFz2TJRUSU6JRWK=
ATN-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHPrVItKSzVyPU[uNFU2PjhizszNMoS3V2FPT0WU
BxPC-3NVGyWIZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTZwMEiyNVkh|ryPNYf1RYxRW0GQR1XS
KYSE-150NXjZNHllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3z6fGlEPTB;Nj6xNlQ4PiEQvF2=NH\SdopUSU6JRWK=
RPMI-8866MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYXhWmgxUUN3ME22MlE6OTZ|IN88US=>MkLlV2FPT0WU
SW780M1W1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIPn[5pKSzVyPU[uNlA1OiEQvF2=NEPpVlVUSU6JRWK=
A388MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfDfGxFUUN3ME22MlI{OTF3IN88US=>NVLyS3NuW0GQR1XS
NCI-H1437M{LuOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXMTWM2OD14LkK0NFc{KM7:TR?=NWnweXY6W0GQR1XS
NCI-H1755MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7qN29KSzVyPU[uN|Y3OTJizszNM{nKbHNCVkeHUh?=
LS-123MmLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoTZTWM2OD14LkSwOVIyKM7:TR?=NHXD[W1USU6JRWK=
CaR-1MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTZwNE[zO|Mh|ryPNH62U4pUSU6JRWK=
RT-112M2HNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEfoVm9KSzVyPU[uOlA{OzhizszNMVfTRW5ITVJ?
CGTM4jNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXYTWM2OD14LkezOlgyKM7:TR?=NHfxTJJUSU6JRWK=
SW626NVj1fnNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLyS2M6UUN3ME22Mlc{QTR4IN88US=>NHL1e3JUSU6JRWK=
AsPC-1MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGfRTW9KSzVyPU[uO|Q2ODdizszNNGeyVWFUSU6JRWK=
SBC-5NF\qZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTZwOUeyPVch|ryPMWHTRW5ITVJ?
SF539NFzncHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTZwOUmzN|Mh|ryPM1P3O3NCVkeHUh?=
TI-73MmTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrrTVNKSzVyPUeuNFYzQDVizszNNIXyW4hUSU6JRWK=
MHH-ES-1MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\QW4RtUUN3ME23MlA4PzZ{IN88US=>NEPnOZhUSU6JRWK=
KYSE-510MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vPVGlEPTB;Nz6wPFQ{OiEQvF2=M2\mb3NCVkeHUh?=
EW-1M1T6cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjlNYN[UUN3ME23MlM3QTl4IN88US=>MVXTRW5ITVJ?
SK-OV-3NIHFfpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DvW2lEPTB;Nz6zPVQ{OiEQvF2=M2q2SnNCVkeHUh?=
MC-IXCM3LTN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mme2TWM2OD15LkSxPVczKM7:TR?=NYr2ZXhvW0GQR1XS
HSC-2NWHISZVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\zd2lEPTB;Nz60NlcxPSEQvF2=Mk\SV2FPT0WU
NCI-H2342NFztTnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIfiSXpKSzVyPUeuOVE1QSEQvF2=NH61dGpUSU6JRWK=
NCI-H1792MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGHvOGdKSzVyPUeuOVE4OTFizszNMXvTRW5ITVJ?
HT-1376NWG2VXB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHWyZndKSzVyPUeuPFc4PzhizszNMoK2V2FPT0WU
EW-13MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTdwOEm5O|ch|ryPMV7TRW5ITVJ?
no-11MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3GzeWlEPTB;Nz65NFE4PCEQvF2=MVTTRW5ITVJ?
DaoyNEe0XIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTdwOUSzNlEh|ryPNULTRYlWW0GQR1XS
COLO-800MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3YTWM2OD16LkC0NVYzKM7:TR?=Mo\0V2FPT0WU
GB-1NETu[ppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLEbW9KSzVyPUiuNFY2PjVizszNNHziTWpUSU6JRWK=
SJRH30NH;VWphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLid2ljUUN3ME24MlE2QDd6IN88US=>M3uzRXNCVkeHUh?=
NCI-H2291M3vBV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml64TWM2OD16LkK5NVg4KM7:TR?=MnvaV2FPT0WU
J82NWLWO2FUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXGTWM2OD16LkK5OFkyKM7:TR?=NGL3R3RUSU6JRWK=
NCI-H596NVHKeHB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHvyfoNKSzVyPUiuN|E1PTNizszNMkPPV2FPT0WU
RERF-LC-MSMnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRThwM{S4OVYh|ryPM4ToWHNCVkeHUh?=
RH-18NWjKSIM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHvS|R4UUN3ME24MlM2ODR4IN88US=>Mm\rV2FPT0WU
SW48NWq3ZpJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXrTWM2OD16LkW5OFU{KM7:TR?=NWjBd3g6W0GQR1XS
RDNHmwTm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzwOmF5UUN3ME24MlU6OzlzIN88US=>M1vj[XNCVkeHUh?=
MS-1MkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjRSHpKSzVyPUiuOlE{QDdizszNMlP0V2FPT0WU
ES6MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoW4TWM2OD16LkezNVE6KM7:TR?=M3\HcHNCVkeHUh?=
TE-12NVu2eXRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYDL[Wd7UUN3ME24Mlc4PTB3IN88US=>NIjU[nZUSU6JRWK=
DBTRG-05MGMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlTCTWM2OD16LkmxNlE4KM7:TR?=NXXz[XBYW0GQR1XS
KINGS-1NFO3bWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH3O[4tKSzVyPUiuPVI6OzhizszNMlLtV2FPT0WU
HLEMmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;vbGlEPTB;OD65N|c5PSEQvF2=M3;1c3NCVkeHUh?=
MHH-NB-11NV;lSYJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV;JR|UxRTlwMEG4N|kh|ryPNWPrdFVwW0GQR1XS
U-87-MGMnPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M160[2lEPTB;OT6yOFMzOSEQvF2=NVTTV|NLW0GQR1XS
MN-60NGHZSVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXy2N2Z{UUN3ME25MlI1PTR{IN88US=>NYfh[2xtW0GQR1XS
SASM{nBcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrHTWM2OD17LkK1OVgyKM7:TR?=MlrNV2FPT0WU
NCI-H446NFnZW4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGnseY5KSzVyPUmuN|YyKM7:TR?=NV7zZo1UW0GQR1XS
C-33-AMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHjFOlBKSzVyPUmuOFM6QDhizszNMn3VV2FPT0WU
RXF393NIfrRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoDLTWM2OD17LkS3NFAzKM7:TR?=NVXGe5ZtW0GQR1XS
CGTH-W-1MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTlwNEmzPFQh|ryPNW\1TGs2W0GQR1XS
RCM-1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4CwbmlEPTB;OT62N|gxOSEQvF2=MorpV2FPT0WU
SN12CMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTlwNkWzN|gh|ryPNYLkT5BmW0GQR1XS
KLENVnnXos1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTlwN{CwNFkh|ryPNYPyUZlFW0GQR1XS
EFO-21NW\y[IRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIj2ZlhKSzVyPUmuO|c{QDJizszNMXLTRW5ITVJ?
KYSE-70NGizXodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVy2eIZOUUN3ME25Mlg5ODFzIN88US=>M172[XNCVkeHUh?=
D-247MGM2P5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnGcVZKSzVyPUGwMlA2PjhizszNNXXpWGF{W0GQR1XS
MPP-89MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEHpNpdKSzVyPUGwMlA6PDZizszNNWG1XYJuW0GQR1XS
RVH-421MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnvrTWM2OD1zMD6xOVA2KM7:TR?=MlrOV2FPT0WU
NCI-H460MojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTFyLkK4NFYh|ryPNXz3UIs{W0GQR1XS
NOMO-1M4G2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFL6TW1KSzVyPUGwMlM2OzJizszNNYn5NXdpW0GQR1XS
DELMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkP3TWM2OD1zMD6zO|k1KM7:TR?=NVz1XpBxW0GQR1XS
HT55MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTFyLk[yNFUh|ryPNGLyU3ZUSU6JRWK=
MC116MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1LnfWlEPTB;MUCuOlY2PSEQvF2=NH7Oc|NUSU6JRWK=
BB30-HNCNYfxWIJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTFyLk[2PUDPxE1?M3;venNCVkeHUh?=
DJM-1NXjvWVZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrreWtKSzVyPUGwMlY6PDlizszNNUPG[VY5W0GQR1XS
ZR-75-30NVfkeVZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3nS4NKSzVyPUGwMlk1PDFizszNNFPYeoRUSU6JRWK=
U-118-MGNX;3UnVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTFyLkm4PVYh|ryPNHiyNnlUSU6JRWK=
MSTO-211HM1Pr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEj5OYFKSzVyPUGxMlA4OTZizszNNXywe|d7W0GQR1XS
SW837NUPhOXBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTFzLkC5OFkh|ryPMXHTRW5ITVJ?
HuCCT1NXLreGpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrEXG9[UUN3ME2xNU4yOjhzIN88US=>MX\TRW5ITVJ?
RCC10RGBM3LSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFH5cpVKSzVyPUGxMlE{PSEQvF2=M1jZbnNCVkeHUh?=
NMC-G1MkTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\STWM2OD1zMT6xOFk{KM7:TR?=MlPGV2FPT0WU
NCI-H650MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkXVTWM2OD1zMT6zO|k1KM7:TR?=MnjGV2FPT0WU
HEC-1NVn3TFBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGTDfWFKSzVyPUGxMlQ{OjhizszNNXLzOJVQW0GQR1XS
DU-4475NYfKUJFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTFzLkezPVMh|ryPM3rl[nNCVkeHUh?=
DSH1NX\QbnVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnLRTWM2OD1zMT63OlA3KM7:TR?=M2rXenNCVkeHUh?=
HCC1569NX3mXHF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH3jWo9KSzVyPUGxMlc3PzhizszNMXXTRW5ITVJ?
HCC1187NYXGW4hLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3FWWROUUN3ME2xNU45PTh6IN88US=>MXLTRW5ITVJ?
EW-11Mn3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHSwWXZKSzVyPUGxMlk1PzRizszNMYXTRW5ITVJ?
LB2518-MELNWTQWWdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTF{LkC1PUDPxE1?NVXXT3U6W0GQR1XS
KALS-1MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTF{Lki1OVMh|ryPMmHUV2FPT0WU
8505CMljQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PDZ2lEPTB;MUKuPFg2KM7:TR?=NHHYVIhUSU6JRWK=
SK-N-DZMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;DOphKSzVyPUGzMlA1PTNizszNMWrTRW5ITVJ?
CHP-134Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NETZU5lKSzVyPUGzMlEyPThizszNMWfTRW5ITVJ?
HCE-TNVLwN3hQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TUPWlEPTB;MUOuNlM3PCEQvF2=NHvRU|BUSU6JRWK=
LB-831-BLCNYfiOmlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{DKWWlEPTB;MUOuOlI1PiEQvF2=MnG1V2FPT0WU
OVCAR-4MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHPNo55UUN3ME2xN{43PTJ2IN88US=>M2ftVXNCVkeHUh?=
SW756NWDMWZFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{T1cWlEPTB;MUOuO|I1PiEQvF2=NWf1fGJzW0GQR1XS
OCUB-MNYm5R3htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFfjc5FKSzVyPUGzMlgyPTZizszNMXzTRW5ITVJ?
SW982NF72OHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTF|LkiyO|Yh|ryPMUnTRW5ITVJ?
DBMmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml76TWM2OD1zMz64N|g1KM7:TR?=MlLNV2FPT0WU
H-EMC-SSMorOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmX1TWM2OD1zMz65NVM6KM7:TR?=NWfyenRCW0GQR1XS
VMRC-RCZMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1zaUWlEPTB;MUSuNFAyPSEQvF2=NWC0WHcyW0GQR1XS
CAKI-1Mk\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{XkfmlEPTB;MUSuNFE{OiEQvF2=MmnDV2FPT0WU
GI-1NF\NWldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVTLdno6UUN3ME2xOE4xPjV6IN88US=>MXXTRW5ITVJ?
Ca9-22NHfGTGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGrTcJVKSzVyPUG0MlYxPTRizszNM4P4bXNCVkeHUh?=
TE-5MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHxcJlPUUN3ME2xOE44OjB6IN88US=>NGK5Z2FUSU6JRWK=
EFO-27NYfIdnRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWmxTIkxUUN3ME2xOE44PjJ{IN88US=>M3zoOnNCVkeHUh?=
CAL-72M1XyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXjNcYMyUUN3ME2xOE44Pzh|IN88US=>MXjTRW5ITVJ?
GP5dNEfHc2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlvKTWM2OD1zNT6wOFc1KM7:TR?=NH7GOXdUSU6JRWK=
CAS-1NFPLWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHvpcZBKSzVyPUG1MlA3PiEQvF2=NXvEOIpDW0GQR1XS
A2058MlPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFTtV3VKSzVyPUG1MlU3OzhizszNNH7nNpZUSU6JRWK=
PANC-08-13MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnj3TWM2OD1zNT62PFU6KM7:TR?=NXqwdIdRW0GQR1XS
Detroit562NU\5NZlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTF3LkmxN|kh|ryPMnewV2FPT0WU
PANC-10-05MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1y2dGlEPTB;MU[uNFgzOSEQvF2=MofXV2FPT0WU
KOSC-2NUHEZlV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnjsTWM2OD1zNj6xNVI2KM7:TR?=NGDS[olUSU6JRWK=
GT3TKBMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjJeGI5UUN3ME2xOk4yQThzIN88US=>Mn6xV2FPT0WU
KM-H2M4Pnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIPpN5FKSzVyPUG2MlM3PDZizszNNGTa[nFUSU6JRWK=
LB771-HNCMnrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{LRTGlEPTB;MU[uOFQzOiEQvF2=M1\LWXNCVkeHUh?=
SF268MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYOxRVZbUUN3ME2xOk41PTJizszNNXTLRlRiW0GQR1XS
OE19MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWKyVpdwUUN3ME2xOk42OjRizszNM3rv[HNCVkeHUh?=
MLMAM4\keGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;4Z2dKSzVyPUG2MlU2PzFizszNMlvNV2FPT0WU
MDA-MB-231MmnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml20TWM2OD1zNj63NVM3KM7:TR?=M4roTnNCVkeHUh?=
TGWNUXDd5lsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHHYdmNKSzVyPUG2MlgyODJizszNNUPBfFMxW0GQR1XS
MDA-MB-453M4P1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEH6W5RKSzVyPUG3MlAxODNizszNNEfrPHBUSU6JRWK=
SNU-C2BM1Pjc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGXSWVlKSzVyPUG3MlAzOzdizszNMUXTRW5ITVJ?
A427Ml7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPXTphKSzVyPUG3MlI{OzRizszNNIjpdmVUSU6JRWK=
SK-MEL-2NXn5U3M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGfJO4tKSzVyPUG3MlMzOTNizszNMXzTRW5ITVJ?
KURAMOCHINYfmUW57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\HTWM2OD1zNz6zPFk4KM7:TR?=MUfTRW5ITVJ?
IST-MEL1Ml3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXqxS4Q2UUN3ME2xO{46OTh{IN88US=>MUfTRW5ITVJ?
NCI-H1793M1fUZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1PnUWlEPTB;MUiuNVU5OSEQvF2=M{PISXNCVkeHUh?=
HCC1395MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTF6LkW2NVEh|ryPNFXrTYFUSU6JRWK=
NUGC-3MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LScmlEPTB;MUiuOlU5PCEQvF2=NELFOZFUSU6JRWK=
BB65-RCCMmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;INZlKSzVyPUG4MlY3QSEQvF2=NUOwe5hPW0GQR1XS
RMG-INX:xbYk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTF6LkezPFIh|ryPMljrV2FPT0WU
LS-513M2P6e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTF6LkmyNlgh|ryPMVvTRW5ITVJ?
MFM-223NHzOXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Moi4TWM2OD1zOT6wO|E3KM7:TR?=NWXweIlDW0GQR1XS
NCI-H727NGj5R41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHvvb2pKSzVyPUG5MlMzQTVizszNMVfTRW5ITVJ?
KP-4M4nIXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTF7Lki1N|Eh|ryPNEi2[2lUSU6JRWK=
NB13M1;qdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX6zVG5MUUN3ME2xPU45QDN7IN88US=>NYX4NopXW0GQR1XS
UACC-893MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHmyW5pKSzVyPUG5Mlk4PTdizszNMnLRV2FPT0WU
HT-1197MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LPSGlEPTB;MkCuNlk2QCEQvF2=NFT3VZNUSU6JRWK=
NCI-H2029NWnQWW5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTJyLkOyOlYh|ryPMoP6V2FPT0WU
GI-ME-NMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHyTWM2OD1{MD6zN|c{KM7:TR?=MlrFV2FPT0WU
OVCAR-3NYrOemVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTJyLkW4NlIh|ryPNGjZTZhUSU6JRWK=
HD-MY-ZNVr3dpR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWXLcXZkUUN3ME2yNU4{Pjl4IN88US=>NF7YTo1USU6JRWK=
NTERA-S-cl-D1NETTU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTJzLk[3NlIh|ryPMXTTRW5ITVJ?
SCHMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXP3Wm92UUN3ME2yNk41QTZizszNMXHTRW5ITVJ?
KARPAS-299NXny[nBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTJ|LkO4PFch|ryPMX;TRW5ITVJ?
NCI-H1650NFvtXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYPocmcyUUN3ME2yN{46OjRzIN88US=>MWTTRW5ITVJ?
ACHNM4P1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTBOoNKSzVyPUK0MlQ3PTZizszNNHXGbFdUSU6JRWK=
M059JM4HtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkLUTWM2OD1{ND61OlM1KM7:TR?=NXTkcpNYW0GQR1XS
AM-38M2PkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTJ3LkS4NUDPxE1?MV;TRW5ITVJ?
KG-1NFTyNJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEewSFZKSzVyPUK1MlU1QTRizszNM4iweHNCVkeHUh?=
COLO-824M3z0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk[wTWM2OD1{NT61OVk6KM7:TR?=NVfJdZhqW0GQR1XS
NCI-H1155MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NITkWoNKSzVyPUK1MlU5PDdizszNM2[4TXNCVkeHUh?=
NCI-H441NIPTb3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWjUSVZjUUN3ME2yOU44PDZ3IN88US=>M2rpeXNCVkeHUh?=
J-RT3-T3-5NIq2T2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1Pvb2lEPTB;Mk[uN|AzPyEQvF2=M4PNZXNCVkeHUh?=
JEG-3MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGf3WlRKSzVyPUK2MlY5ODVizszNNGrjO25USU6JRWK=
RKONYT3UJNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NInUemlKSzVyPUK2Mlc3OzJizszNNXP4R2JbW0GQR1XS
CAL-85-1MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRTJ5LkKxNVgh|ryPM1LZfXNCVkeHUh?=
CAL-120MmPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml7oTWM2OD1{Nz62PVE1KM7:TR?=M4nQenNCVkeHUh?=
NCI-H2452M3HLNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTJ5Lke3NVYh|ryPNY\zToZ6W0GQR1XS
NCI-H1395MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWTXfno3UUN3ME2yO{44QDN|IN88US=>MmKwV2FPT0WU
KYSE-450M4L3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTJ5Lkm4OlIh|ryPM{HjUHNCVkeHUh?=
S-117M1;GUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4PZdmlEPTB;MkmuN|g2PyEQvF2=NFzyWVhUSU6JRWK=
SW13M1nOOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTJ7Lki1NVkh|ryPNV\jUZRkW0GQR1XS
ES3NIT5OVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3fz[2lEPTB;M{CuN|c{OyEQvF2=NVf5VnVHW0GQR1XS
HCT-116MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkH2TWM2OD1|MD61OVU1KM7:TR?=NHW5cYZUSU6JRWK=
NCI-H1693NYfRV4ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLGUFJKSzVyPUOwMlU6PDJizszNMl3CV2FPT0WU
VM-CUB-1NVH5OWJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTNyLk[0NVMh|ryPM4XHZ3NCVkeHUh?=
NCI-H2170NFXvTpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7JTWM2OD1|MT61O|g1KM7:TR?=M1XPfnNCVkeHUh?=
ALL-POMmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHmUXNKSzVyPUOxMlg1OjhizszNNGG0eXJUSU6JRWK=
NCI-H661MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU\rSnhiUUN3ME2zNk4xPjJ|IN88US=>MmDpV2FPT0WU
NCI-H2347MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmDaTWM2OD1|Mj60PFM4KM7:TR?=NXrVb21tW0GQR1XS
FTC-133MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PDSWlEPTB;M{KuO|A3KM7:TR?=NEPUbpRUSU6JRWK=
COLO-829NGiy[|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljFTWM2OD1|Mz6zOFY4KM7:TR?=M4\qd3NCVkeHUh?=
GOTONELXcJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTN|LkWyOVgh|ryPMWLTRW5ITVJ?
YAPCMmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTN|LkixOVkh|ryPNVjRcppTW0GQR1XS
LCLC-103HMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGi5[GRKSzVyPUO0MlE3OjRizszNM3vvc3NCVkeHUh?=
SiHaM1HHXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXy0[FFmUUN3ME2zOE4{QDF5IN88US=>NWHQVYJEW0GQR1XS
LK-2MkGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoryTWM2OD1|ND61O|A5KM7:TR?=MkK1V2FPT0WU
KP-N-YSMkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLNTWM2OD1|ND63NlAzKM7:TR?=NG[3SmxUSU6JRWK=
NCI-SNU-1Mon6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4r1fWlEPTB;M{WuNVc6KM7:TR?=NH\FV29USU6JRWK=
KNS-81-FDM1rPemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1\KUmlEPTB;M{WuOlY{KM7:TR?=NEfxSIdUSU6JRWK=
SCC-9MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MofrTWM2OD1|Nj63NVQ3KM7:TR?=M1TJd3NCVkeHUh?=
SH-4M4nkWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkL2TWM2OD1|Nj63N{DPxE1?NVflV4pDW0GQR1XS
HCC-1954NFnzRnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVGye|Y1UUN3ME2zO{4zPzJ7IN88US=>MoLFV2FPT0WU
BALL-1NXG0PGVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXXhZmNYUUN3ME2zO{42OzF4IN88US=>MnL3V2FPT0WU
BE-13NUnYPXllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2rL[WlEPTB;M{euO|AyQCEQvF2=NFXsXohUSU6JRWK=
COLO-678Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1z3RWlEPTB;M{euPVQ{PyEQvF2=MXHTRW5ITVJ?
SK-MEL-3NXn5bpRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTN6LkKzPVch|ryPNWj2RWVHW0GQR1XS
OAW-28M3PEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmDxTWM2OD1|OD62N|kh|ryPNGLZZXZUSU6JRWK=
CAMA-1MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;hTWM2OD1|OD65OlkyKM7:TR?=M3q2THNCVkeHUh?=
C2BBe1NHvXSHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3uyNWlEPTB;M{muPFE5KM7:TR?=NFvHNmZUSU6JRWK=
A3-KAWM1LlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NULJN|lZUUN3ME20NE4{PjZzIN88US=>NGXqdmtUSU6JRWK=
SK-MEL-24M1LhNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTRyLkW5N|Eh|ryPM2LzOHNCVkeHUh?=
KYSE-140NIXzeJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHX6TYtKSzVyPUSwMlcyPjVizszNMUfTRW5ITVJ?
MOLT-16NEPvdIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTRzLkG1N|Yh|ryPMXnTRW5ITVJ?
CFPAC-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTR{LkWyNVEh|ryPNWnaVWFFW0GQR1XS
NB14NVSzfGVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;idWlEPTB;NEKuO|AzPyEQvF2=M2PJNHNCVkeHUh?=
COLO-792MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml70TWM2OD12Mj64PVYyKM7:TR?=Ml\hV2FPT0WU
RH-1NFjOSJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlHMTWM2OD12Mz60PFM3KM7:TR?=MWXTRW5ITVJ?
NCI-H522NIDJNlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTR2LkO1Olgh|ryPM2e0NHNCVkeHUh?=
Ca-SkiMn:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTR2LkixNVQh|ryPM2XM[3NCVkeHUh?=
KGNNVuybHh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\wUXBKSzVyPUS4MlMxPjNizszNM1v4Z3NCVkeHUh?=
UACC-62NEezR3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;qW|hKSzVyPUS4MlQxPzJizszNMUfTRW5ITVJ?
NCI-H358MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnmRY9KSzVyPUS5MlMxOThizszNNH7rWVNUSU6JRWK=
LS-411NNH;hcJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mme1TWM2OD12OT6zNVE5KM7:TR?=NXXPTIJxW0GQR1XS
IST-MES1MoG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\HTWM2OD12OT61OlI2KM7:TR?=NXS2VohmW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Administration of GDC-0941 at 75 mg/kg/day displays significant inhibitory effect against established human U87MG glioblastoma xenografts in female NCr athymic mice, with tumor growth inhibition of 83%. [1] Oral administration of GDC-0941 at 150 mg/kg/day inhibits the growth of HER2-amplified, trastuzumab-resistant MDA-MB-361.1 xenografts in mice, and significantly delays the tumor progression, in association with potent induced apoptosis in tumors. [2] GDC-0941 (75 mg/kg/day) treatment for 2 weeks induces ~40% reduction in tumor volume of spontaneous B-cell follicular lymphomas developed in PTEN+/-LKB1+/hypo mice, accompanied by ablation of phosphorylation of Akt, S6K and SGK (serum and glucocorticoid protein kinase) protein kinases. [4]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Scintillation proximity assay Recombinant human PI3Kα, PI3Kβ, and PI3Kδ are coexpressed in a Sf9 baculovirus system with the p85α regulatory subunit and purified as GST-fusion proteins using affinity chromatography on glutathione-sepharose. Recombinant human PI3Kγ is expressed as monomeric GST-fusions and purified similarly. GDC-0941 is dissolved in DMSO and added to 20 mM Tris-HCl (pH 7.5) containing 200 μg yttrium silicate (Ysi) polylysine SPA beads, 4 mM MgCl2, 1 mM dithiothreitol (DTT), 1 μM ATP, 0.125 μCi [γ-33P]-ATP, and 4% (v/v) DMSO in a total volume of 50 μL. The recombinant GST-fusion of PI3Kα (5 ng), PI3Kβ (5 ng), PI3Kδ (5 ng), or PI3Kγ (5 ng) is added to the assay mixture to initiate the kinase reaction. After incubation for 1 hour at room temperature, the kinase reaction is terminated with 150 μL PBS. The mixture is then centrifuged for 2 minutes at 2000 rpm and read using a Wallac Microbeta counter. The reported IC50 values are calculated using a sigmoidal, dose-response curve fit in MDL Assay Explorer.

Cell Assay: [2]

Cell lines SKBR-3, BT474-M1, AU-565, HCC-1419, ZR75-30, KPL-4, JIMT-1, BT474-EEI, HCC-1954, MCF-7, CALU-3, SKOV-3, and MKN-7 cells
Concentrations Dissolved in DMSO, final concentrations ~10 μM
Incubation Time 48 and 72 hours
Method Cells are exposed to various concentrations of GDC-0941 for 48, and 72 hours. Proliferation/viability of cells is detected by using the CellTiter-Glo Luminescent Cell Viability Assay. The pAkt (Ser473), cleaved caspase-3, and cleaved PARP are analyzed by western blot. The Caspase-Glo 3/7 assay and the Cell Death Detection ELISAplus assay are used to detect caspase 3/7 activity, and apoptosis, respectively.

Animal Study: [2]

Animal Models NCR nude mice implanted with MDA-MB-361.1 cells, and SCID, C.B-17/IcrHsd-Prkdcscid mice implanted subcutaneously with BT474-M1 cells
Formulation Dissolved in 10% DMSO, 5% Tween 20, 85% water
Dosages ~150 mg/kg/day
Administration Oral gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Folkes AJ, et al. J Med Chem, 2008, 51(18), 5522-5532.

[2] Junttila TT, et al. Cancer Cell, 2009, 15(5), 429-440.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-05-07)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02092831 Completed Healthy Volunteer Genentech, Inc. April 2014 Phase 1
NCT01740336 Active, not recruiting Breast Cancer Genentech, Inc. February 2013 Phase 2
NCT01493843 Completed Non-Squamous Non-Small Cell Lung Cancer Genentech, Inc. January 2012 Phase 2
NCT01474668 Completed Healthy Volunteer Genentech, Inc. October 2011 Phase 1
NCT01437566 Active, not recruiting Breast Cancer Genentech, Inc. June 2011 Phase 2

view more

Chemical Information

Download Pictilisib (GDC-0941) SDF
Molecular Weight (MW) 513.64
Formula

C23H27N7O3S2

CAS No. 957054-30-7
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms RG7321
Solubility (25°C) * In vitro DMSO 44 mg/mL (85.66 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidine

Customer Product Validation (7)


Click to enlarge
Rating
Source Cancer Res 2011 71, 2750-2760. Pictilisib (GDC-0941) purchased from Selleck
Method Western blot, Immunofluorescence staining, flow cytometry
Cell Lines 1205Lu cells
Concentrations 3 µmol/L
Incubation Time 48 h
Results Combined PI3K and BRAF inhibition increased the level of BIM expression in both Western blot and immunofluorescence studies (Fig. A). Consistent with a role for increased AKT signaling suppressing BIM expression in PTEN- cells, dual BRAF and PI3K inhibition increased nuclear FOXO3a localization in the PTEN- cell lines (Fig. B) and enhanced the level of BIM mRNA (Fig. B). the combination of PLX4720 with the PI3K inhibitor GDC-0941 significantly enhanced the levels of apoptosis observed in PTEN melanoma cell lines compared to either the BRAF or PI3K inhibitor alone (Fig. C). Similar results were also observed in a 3D spheroid assay, where combined PLX4720 (3 µmol/L) and LY294002 (10 µmol/L) treatment prevented the recovery of cell growth observed when melanoma spheroids were treated with either drug alone (Fig. D).

Click to enlarge
Rating
Source J Inves Der 2010 131, 495-503. Pictilisib (GDC-0941) purchased from Selleck
Method Western blot
Cell Lines Mel-Juso cells, 518A2 cells
Concentrations 0.05–1 µmol/L
Incubation Time 24 h
Results In addition, GDC-0941 treatment blocked the phosphorylation of AKT protein (S473 and T308) at even lower concentrations than PI-103, and S6 protein phosphorylation was blocked at similar concentrations.

Click to enlarge
Rating
Source J Cell Sci 2012 125(Pt 5), 1259-73. Pictilisib (GDC-0941) purchased from Selleck
Method Western Blot
Cell Lines NMuMG cells
Concentrations 1 μM
Incubation Time 1 h
Results GDC-0941, a specific inhibitor of the class IA PI3K, similarly blocked the TGF-b-induced Akt(S473) phosphorylation, confirming the role of PI3K in the induction of mTORC2 kinase activity by TGF-β (Fig. C).

Click to enlarge
Rating
Source Biochim Biophys Acta 2012 1823, 2210-6. Pictilisib (GDC-0941) purchased from Selleck
Method confocal laser-scanning microscopy
Cell Lines HEK293 cells
Concentrations 1 μM
Incubation Time 30 min
Results Both LY294002 and GDC-0941 markedly attenuated the high-glucose-dependent plasma membrane translocation of DGKδ1, indicating that the event is positively regulated by phosphatidylinositol 3-kinase.

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. Pictilisib (GDC-0941) purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-10 nM
Incubation Time 3 h
Results

Click to enlarge
Rating
Source Saraswati Sukumar of Johns Hopkins University School of Medicine. Pictilisib (GDC-0941) purchased from Selleck
Method Western blot
Cell Lines T47D cells
Concentrations
Incubation Time 1 h
Results

Click to enlarge
Rating
Source Pictilisib (GDC-0941) purchased from Selleck
Method Western blot analysis
Cell Lines MCF-7 cells
Concentrations 0 nM/50 nM/100 nM/400 nM
Incubation Time 24 h
Results GDC-0941 caused a surprising increase in phosphorylation of ERK proteins as well as AKT2 S474. GDC-0941 showed differences in its ability to suppr ess PI3K-dependent signaling across the genotypes. AKT1 mutant cells demonstrated greater residual AKT1 S473 phosphorylation and greater phosphorylation of downstream proteins FOXO 1/3, PRAS40, GSK3β , and p70S6K at equivalent doses of GDC-0941, compared to PIK3CA mutant cells.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related PI3K Products

  • GDC-0032

    GDC-0032 is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with Ki of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147)

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • GNE-317

    GNE-317 is a potent, brain-penetrant PI3K inhibitor.

  • LY294002

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.

  • CAL-101 (Idelalisib, GS-1101)

    CAL-101 (Idelalisib, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.

  • Wortmannin

    Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

  • BEZ235 (NVP-BEZ235, Dactolisib)

    BEZ235 (NVP-BEZ235, Dactolisib) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3TopBP1-ER cell.

  • BKM120 (NVP-BKM120, Buparlisib)

    BKM120 (NVP-BKM120, Buparlisib) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.

  • Alpelisib (BYL719)

    Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Recently Viewed Items

Tags: buy Pictilisib (GDC-0941) | Pictilisib (GDC-0941) supplier | purchase Pictilisib (GDC-0941) | Pictilisib (GDC-0941) cost | Pictilisib (GDC-0941) manufacturer | order Pictilisib (GDC-0941) | Pictilisib (GDC-0941) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us